

Supplementary Table 4. Risk factors of immunosuppressant use in ulcerative colitis patients

Characteristic	Univariate analysis		Multivariate analysis	
	7-Year cumulative rate, %	p value	HR (95% CI)	p value
Baseline at diagnosis				
Age, yr		0.001		
≥ 20	36.3		Reference	
< 20	19.0		2.13 (1.22–3.70)	0.008
Sex		0.032		
Female	16.7		Reference	
Male	22.1		0.78 (0.56–1.09)	0.150
Body mass index, kg/m ²		0.024		
≥ 23	19.5		Reference	
< 23	23.6		1.27 (0.92–1.75)	0.140
Family history of IBD		0.751		
No	24.0		Reference	
Yes	9.3		0.50 (0.12–2.05)	0.333
Smoking status		0.434		
No	28.3		Reference	
Yes	26.1		1.15 (0.79–1.68)	0.478
Disease activity at diagnosis		0.000		
Mild	15.3		Reference	
Moderate	45.2		1.97 (1.34–2.90)	0.001
Severe	42.3		2.21 (1.30–3.76)	0.003
Montreal classification of extent of UC		0.000		
E1 (ulcerative proctitis)	7.1		Reference	
E2 (left-sided UC)	26.4		2.80 (1.66–4.72)	0.000
E3 (extensive UC)	34.1		3.23 (1.89–5.54)	0.000
Treatment				
UC-related admission		0.000		
No	8.5		Reference	
Yes	36.3		0.98 (0.62–1.53)	0.915
UC-related operation		0.011		
No	18.9		Reference	
Yes	34.2		1.16 (0.67–2.02)	0.591
Medication				
Oral steroids		0.000		
No	1.1		Reference	
Yes	34.7		26.72 (6.71–114.58)	0.000
IV steroids		0.000		
No	12.4		Reference	
Yes	56.6		1.49 (1.03–2.16)	0.036
Infliximab		0.000		
No	16.1		Reference	
Yes	79.9		3.02 (2.11–4.30)	0.000

HR, hazard ratio; CI, confidence interval; IBD, inflammatory bowel disease; UC, ulcerative colitis; IV, intravenous.